Cargando…
Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients
The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...
Autores principales: | Alexandre, Marina, Bohelay, Gérôme, Gille, Thomas, Le Roux-Villet, Christelle, Soued, Isaac, Morin, Florence, Caux, Frédéric, Grootenboer-Mignot, Sabine, Prost-Squarcioni, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065717/ https://www.ncbi.nlm.nih.gov/pubmed/35514989 http://dx.doi.org/10.3389/fimmu.2022.874108 |
Ejemplares similares
-
Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients
por: Bohelay, Gérôme, et al.
Publicado: (2022) -
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature
por: Zumelzu, Coralie, et al.
Publicado: (2018) -
Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients
por: Gaudin, Olivier, et al.
Publicado: (2018) -
Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa
por: Yatim, Ahmad, et al.
Publicado: (2019) -
Increasing evidence for omalizumab in the treatment of bullous pemphigoid
por: Lonowski, Sarah, et al.
Publicado: (2020)